CTI Clinical Trial and Consulting Services (CTI) has acquired Community Research, a specialty clinical research site with three locations throughout Cincinnati, OH. Community Research conducts Phase I-IV trials in various therapeutic areas, including internal medicine, dermatology, psychiatry, and sleep disorders. Its hospital-based Phase I facility can accommodate drug and device trials, with a special focus on first-in-human studies in various patient populations. Financial terms were not disclosed.
David Mayleben, Ph.D., president and co-founder of Community Research, will serve as vice president at CTI, and will continue to lead the research centers. Co-founder, Dr. Bruce Corser, will serve as a consultant for CTI. Community Research’s 50 employees will join CTI.
“This is a great opportunity to strengthen the offerings that Community Research provides to those in the pharmaceutical and biotechnology industries,” said Dr. Mayleben. “We have worked with CTI many times over the past several years and are excited for this new endeavor.”
“We are looking forward to the integration of both companies and adding the strong operational expertise Community Research has to our own organization,” said Kevin Schwarz, chief operating officer of CTI. “We feel that Community Research provides us with even greater service offerings for our clients, who include more than 70 pharmaceutical and biotechnology companies around the world.”